ICAR GUIDELINES Bundle (free trial)

Rhinology and Allergy Rhinosinusitis

ICAR IFAR GUIDELINES brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512430

Contents of this Issue

Navigation

Page 25 of 27

26 Levels of Evidence Level Diagnosis Therapy/Prevention/Etiology 1 Systematic review of cross sectional studies with consistently applied reference standard and blinding Systematic review of randomized trials or n-of-1 trials 2 Individual cross sectional studies with consistently applied reference standard and blinding Randomized trial or observational study with dramatic effect 3 Cohort study or control arm of randomized trial a Non-randomized controlled cohort/follow-up study b 4 Case-series or case control studies, or poor quality prognostic cohort study b Case-series, case-control studies, or historically controlled studies b 5 Not applicable Mechanism-based reasoning a Level may be graded down on the basis of study design, inconsistency between studies, indirectness of evidence, imprecision, or because the absolute effect size is very small; level may be graded up if there is a large or very large effect size or if a significant dose-response relationship is demonstrated. b As always, a systematic review is generally better than an individual study. Aggregate Grade of Evidence Grade Research Quality A Well-designed RCTs B RCTs with minor limitations Overwhelming consistent evidence from observational studies C Observational studies (case control and cohort design) D Expert opinion Case reports Reasoning from first principles For topics with more limited evidence, the evidence-based review (EBR) process was completed with the evidence table. For those topics with sufficient evidence to produce a recommendation (i.e., an evidence-based review with recommendations [EBRR]), a recommendation using the American Academy of Pediatrics (AAP) guidelines was produced. It is important to note that each evidence-based recommendation took into account the aggregate grade of evidence along with the balance of benefit, harm, and costs (AAP Defined Strateg y for Recommendation Development).

Articles in this issue

view archives of ICAR GUIDELINES Bundle (free trial) - Rhinology and Allergy Rhinosinusitis